

Winter Wonderland Skin Care

(NAPSA)—In the middle of the cold, dark winter it's easy to forget the importance of protecting our skin from the sun. After months of walking around all bundled up, many of us jet off for winter vacations. Though it's tempting to hit the beach or slopes the moment we arrive on vacation, winter skin is particularly vulnerable to sunburn and other conditions exacerbated by the sun. Whether at home, or on a trip, you should remember to protect yourself from overexposure to UV rays.

One of the most common and yet under-diagnosed skin problems precipitated by sun exposure is melasma, a pigmentary disorder caused by excessive production of melanin resulting from hormone imbalance due to recent pregnancy, birth control pills or hormonal changes during menopause. Melasma affects primarily women in their reproductive years and is characterized by dark spots or blotches on the face, forehead and neck. The American Academy of Dermatology estimates that five to six million American women have the disorder. Exposure to sunlight and UV rays often intensifies discoloration of the skin.

Winter is the perfect time to speak to your dermatologist about a healthy skincare regimen and treatment options for Melasma. Tri Luma[®] Cream (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%), is a product clinically proven to reduce the appearance of melasma after eight weeks of use.

Mild to moderate redness, peeling, burning, dryness, or itching



may be experienced. This product contains sulfites that may cause severe allergic reactions including anaphylactic symptoms and life-threatening asthma attacks. Exposure to sunlight, sunlamps, or UV light and extreme heat, wind, or cold should be avoided. Use of a sunscreen with an appropriate SPF of 30 or higher is required. Wear protective clothing and change to nonhormonal forms of birth control, if hormonal methods are used.

Tri-Luma[®] Cream contains hydroquinone, which may produce exogenous ochronosis, a gradual blue-black darkening of the skin, whose occurrence should prompt discontinuation of therapy. Tri-Luma[®] Cream contains the corticosteroid fluocinolone acetonide. Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticoid insufficiency after withdrawal of treatment.

You can view the Web site at www.triluma.com.